Mind Medicine MindMed

Mind Medicine (MindMed), Inc. operates as a neuro-pharmaceutical company that discovers, develops and deploys psychedelic medicines to improve health, promote wellness and alleviate suffering. The firm develops a non-hallucinogenic version of the psychedelic ibogaine. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn in 2019 and is headquarter in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mind Medicine (MNMD) reports robust financials and advances in psychedelic research

Mind Medicine (MNMD) showcased strong financials, R&D progress, and strategic advancements in its Q4 2022 earnings call.
The company's focus on safety, responsible distribution, and talent acquisition positions it well for future growth and innovation.
Challenges in patient enrollment, dosing strategies, and commercialization strategies require strategic planning and clear execution for success.

Mind Medicine (MNMD) reports positive trial data and strong financials

Mind Medicine (MNMD) showcases progress in pipeline development with positive trial results and a strong financial position. The company's focus on advancing treatments for brain health disorders and efficient cash management highlights its commitment to growth and innovation.

MindMed (MNMD) reports Q2 loss, progresses on innovative treatments

MindMed (MNMD) is advancing its R&D pipeline with a focus on MM-120 for GAD and MM-402 for Autism spectrum disorder. Financially, the company maintains a strong position with cash reserves for ongoing operations. Emphasis on placebo-controlled research and innovative formulation technologies highlights a commitment to scientific rigor and product development.

Mind Medicine (MNMD) reports strong financials and promising R&D progress

Mind Medicine (MNMD) is making significant strides in developing innovative treatments for mental health disorders, with promising lead candidates MM-120 and MM-402. While facing increased R&D expenses and analyst scrutiny, the company's strong financial position and focus on unmet needs present opportunities for future growth.

MindMed reports positive Phase IIb results for MM120 in GAD

MindMed's financial performance in 2023 reflected a net loss of $95.7 million but maintained a strong cash position of $99.7 million.
The Phase IIb trial results for MM120 in GAD were positive, demonstrating significant reductions in HAM-A scores and high clinical response rates.
While facing challenges in trial design and demonstrating drug effects, MindMed remains focused on innovation and addressing unmet medical needs.
Opportunities lie in expanding product indications, developing new therapies, and engaging with regulatory authorities to advance their pipeline.

MindMed reports strong Q1 earnings, advances transformative treatments

MindMed's financials remain strong with significant cash reserves and positive trial outcomes for MM-120.
Strategic focus on advancing MM-120 and MM-402 programs while exploring market dynamics and treatment expansion.
Challenges include managing expenses to sustain financial health and interpreting trial data for future research.
Opportunities lie in exploring additional indications, commercial planning, and reshaping patient care with transformative treatments.

MindMed reports strong Q2 earnings, advances Phase III programs

Mind Medicine (MNMD) showcased strong performance in Phase III programs, fundraising, and financials, positioning the company well for future growth and clinical advancements.
With a focus on operational efficiency, patient recruitment, and data integrity, MindMed is poised to address unmet needs in brain health disorders and drive market expansion.
Challenges lie in meeting upcoming milestones, global market analysis, and maintaining data integrity in Phase III trials, but opportunities abound in R&D expansion and market penetration strategies.
Overall, MindMed's strategic focus on Phase III trials, regulatory pathways, and market launch strategies sets a clear path for future success and growth in the brain health sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Mind Medicine (MindMed) Inc (NASDAQ:MNMD) (NEO: MMED), a leading medicine biotech company in psychedelics, this week began trading on the Nasdaq exchange. In light of the momentous occasion, Benzinga spoke with MindMed co-founder and CEO J.R.

MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine

MindMed (MNMD) stock isn't doing so hot with shares taking a beating on the first day of trading at their new home on the Nasdaq. The post MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading appeared first on InvestorPlace.

MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of Trading

MindMed stock rose in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to land on a major U.S. exchange.  The post MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream appeared first on Investor's Business Daily.

MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To Mainstream

Mind Medicine Inc. (NASDAQ:MNMD) commenced trading its subordinate voting shares on The Nasdaq Capital Market Tuesday, under the ticker symbol “MNMD,” as previously announced.   The psychedelic medicine biotech company said it will continue to list on the Neo Exchange Inc. under the symbol “MMED,” while subordinate voting shares will transform from the OTCQB under the symbol “MMEDF” to “MNMD.

Psychedelics Stock MindMed Debuts On Nasdaq

NEW YORK, April 27, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD, NEO: MMED, DE: MMQ), a leading psychedelic medicine biotech company, is pleased to announce the start of trading on The Nasdaq Capital Market ("Nasdaq"). Trading will begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq.

MindMed Begins Trading on Nasdaq

Clinical-stage psychedelic medicine and biotech company Mind Medicine Inc (OTC:MMEDF), also known as MindMed, is surging again Monday ahead of its Nasdaq debut. The company's mission is "to discover, develop and deploy psychedelic inspired medicines and therapies to address addiction and mental illness," according to CEO J.R.

MindMed Surges Ahead Of Nasdaq Debut

As MNMD stock gets ready for its Nasdaq uplisting, the company is seeing rapid gains pushing its price to new highs. The post MNMD Stock: 9 Things to Know Before MindMed Hits the Nasdaq on April 27 appeared first on InvestorPlace.

MNMD Stock: 9 Things to Know Before MindMed Hits the Nasdaq on April 27

COMPASS Pathways

Magic mushrooms and other hallucinogens are becoming a big business.

If You Missed the Cannabis Stock Gold Rush, Try This New Industry Instead

MindMed (MMEDF) stock was getting high on Friday as the penny stock prepares for an uplisting to the Nasdaq Exchange from the OTC Markets. The post MMEDF Stock: 7 Things to Know About Psychedelic Biotech MindMed Ahead of Its Nasdaq Listing appeared first on InvestorPlace.

MMEDF Stock: 7 Things to Know About Psychedelic Biotech MindMed Ahead of Its Nasdaq Listing

Mind Medicine Inc. (NEO: MMED) (OTCQB:MMEDF) (DE: MMQ) confirmed Monday it will commence trading on the Nasdaq Capital Market under the ticker symbol “MNMD” on April 27th. The psychedelic medicine biotech company reported its subordinate voting shares have obtained the necessary authorization to list on Nasdaq.

Psychedelics Stock MindMed Skyrockets On The News Of Nasdaq Trading

NEW YORK, April 23, 2021 /PRNewswire/ -- MindMed (Nasdaq: MNMD) (NEO: MMED) (DE: MMQ), a leading psychedelic medicine biotech company, announced today that the Company's subordinate voting shares have been approved for listing on The Nasdaq Capital Market ("Nasdaq"). Trading is expected to begin on Tuesday, April 27, 2021, under the symbol "MNMD" on the Nasdaq.

MindMed To Commence Trading on Nasdaq

News for Mind Medicine MindMed Stock (MNMD)